Baricitinib-induced paradoxical psoriasis

J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e391-e393. doi: 10.1111/jdv.16293. Epub 2020 Mar 6.

Authors

J Di Domizio¹, J Castagna², M P Algros³, C Prati⁴, C Conrad¹, M Gilliet¹, D Wendling⁴, F Aubin²

Affiliations

¹ Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
² Department of Dermatology, UMR Inserm 1098, Besançon University Hospital, University of Bourgogne Franche Comté, Besançon, France.
³ Deparment of Pathology, University Hospital, Besançon, France.
⁴ Deparment of Rheumatology, UMR Inserm 1098, Besançon University Hospital, University of Bourgogne Franche Comté, Besançon, France.

PMID: 32052886
DOI: 10.1111/jdv.16293

No abstract available

Publication types

Letter

MeSH terms

Azetidines* / adverse effects
Humans
Psoriasis* / chemically induced
Psoriasis* / drug therapy
Purines
Pyrazoles
Sulfonamides / adverse effects

Substances

Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib